Extensions for Using Data Elements from FHIR DSTU2 in FHIR R4B - Downloaded Version null See the Directory of published versions
| Official URL: http://hl7.org/fhir/uv/xver/ValueSet/R2-v2-0292-for-R4B | Version: 0.1.0 | |||
| Standards status: Trial-use | Maturity Level: 0 | Computable Name: R2V20292ForR4B | ||
This cross-version ValueSet represents content from http://hl7.org/fhir/ValueSet/v2-0292|2.8.2 for use in FHIR R4B.
This value set is part of the cross-version definitions generated to enable use of the
value set http://hl7.org/fhir/ValueSet/v2-0292|2.8.2 as defined in FHIR DSTU2
in FHIR R4B.
The source value set is bound to the following FHIR DSTU2 elements:
Across FHIR versions, the value set has been mapped as:
http://hl7.org/fhir/ValueSet/v2-0292|2.8.2http://hl7.org/fhir/ValueSet/v2-0292|2.8.2http://terminology.hl7.org/ValueSet/v2-0292|2.9Note that all concepts are included in this cross-version definition because no concepts have compatible representations
Following are the generation technical comments:
All concepts in the comparison are listed as identical.
The source and target value sets have the same number of active concepts (124).
All concepts in the comparison are listed as identical.
The source and target value sets have the same number of active concepts (124).
FHIR ValueSet http://hl7.org/fhir/ValueSet/v2-0292|2.8.2, defined in FHIR DSTU2 does not have any mapping to FHIR R4B
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://hl7.org/fhir/v2/0292 version 📍1.0.2| Code | Display |
| 01 | DTP |
| 02 | OPV |
| 03 | MMR |
| 04 | M/R |
| 05 | measles |
| 06 | rubella |
| 07 | mumps |
| 08 | Hep B, adolescent or pediatric |
| 09 | Td (adult) |
| 10 | IPV |
| 100 | pneumococcal conjugate |
| 101 | typhoid, ViCPs |
| 102 | DTP-Hib-Hep B |
| 103 | meningococcal C conjugate |
| 104 | Hep A-Hep B |
| 105 | vaccinia (smallpox) diluted |
| 106 | DTaP, 5 pertussis antigens6 |
| 107 | DTaP, NOS |
| 108 | meningococcal, NOS |
| 109 | pneumococcal, NOS |
| 11 | pertussis |
| 110 | DTaP-Hep B-IPV |
| 111 | influenza, live, intranasal |
| 112 | tetanus toxoid, NOS |
| 113 | Td (adult) |
| 114 | meningococcal A,C,Y,W-135 diphtheria conjugate |
| 115 | Tdap |
| 116 | rotavirus, pentavalent |
| 117 | VZIG (IND) |
| 118 | HPV, bivalent |
| 119 | rotavirus, monovalent |
| 12 | diphtheria antitoxin |
| 120 | DTaP-Hib-IPV |
| 121 | zoster |
| 122 | rotavirus, NOS1 |
| 13 | TIG |
| 14 | IG, NOS |
| 15 | influenza, split (incl. purified surface antigen) |
| 16 | influenza, whole |
| 17 | Hib, NOS |
| 18 | rabies, intramuscular injection |
| 19 | BCG |
| 20 | DTaP |
| 21 | varicella |
| 22 | DTP-Hib |
| 23 | plague |
| 24 | anthrax |
| 25 | typhoid, oral |
| 26 | cholera |
| 27 | botulinum antitoxin |
| 28 | DT (pediatric) |
| 29 | CMVIG |
| 30 | HBIG |
| 31 | Hep A, pediatric, NOS |
| 32 | meningococcal |
| 33 | pneumococcal |
| 34 | RIG |
| 35 | tetanus toxoid |
| 36 | VZIG |
| 37 | yellow fever |
| 38 | rubella/mumps |
| 39 | Japanese encephalitis |
| 40 | rabies, intradermal injection |
| 41 | typhoid, parenteral |
| 42 | Hep B, adolescent/high risk infant2 |
| 43 | Hep B, adult4 |
| 44 | Hep B, dialysis |
| 45 | Hep B, NOS |
| 46 | Hib (PRP-D) |
| 47 | Hib (HbOC) |
| 48 | Hib (PRP-T) |
| 49 | Hib (PRP-OMP) |
| 50 | DTaP-Hib |
| 51 | Hib-Hep B |
| 52 | Hep A, adult |
| 53 | typhoid, parenteral, AKD (U.S. military) |
| 54 | adenovirus, type 4 |
| 55 | adenovirus, type 7 |
| 56 | dengue fever |
| 57 | hantavirus |
| 58 | Hep C |
| 59 | Hep E |
| 60 | herpes simplex 2 |
| 61 | HIV |
| 62 | HPV, quadrivalent |
| 63 | Junin virus |
| 64 | leishmaniasis |
| 65 | leprosy |
| 66 | Lyme disease |
| 67 | malaria |
| 68 | melanoma |
| 69 | parainfluenza-3 |
| 70 | Q fever |
| 71 | RSV-IGIV |
| 72 | rheumatic fever |
| 73 | Rift Valley fever |
| 74 | rotavirus, tetravalent |
| 75 | vaccinia (smallpox) |
| 76 | Staphylococcus bacterio lysate |
| 77 | tick-borne encephalitis |
| 78 | tularemia vaccine |
| 79 | vaccinia immune globulin |
| 80 | VEE, live |
| 81 | VEE, inactivated |
| 82 | adenovirus, NOS1 |
| 83 | Hep A, ped/adol, 2 dose |
| 84 | Hep A, ped/adol, 3 dose |
| 85 | Hep A, NOS |
| 86 | IG |
| 87 | IGIV |
| 88 | influenza, NOS |
| 89 | polio, NOS |
| 90 | rabies, NOS |
| 91 | typhoid, NOS |
| 92 | VEE, NOS |
| 93 | RSV-MAb |
| 94 | MMRV |
| 95 | TST-OT tine test |
| 96 | TST-PPD intradermal |
| 97 | TST-PPD tine test |
| 98 | TST, NOS |
| 99 | RESERVED - do not use3 |
| 998 | no vaccine administered5 |
| 999 | unknown |
This value set expansion contains 124 concepts.
| System | Version | Code | Display | JSON | XML |
http://hl7.org/fhir/v2/0292 | 1.0.2 | 01 | DTP | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 02 | OPV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 03 | MMR | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 04 | M/R | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 05 | measles | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 06 | rubella | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 07 | mumps | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 08 | Hep B, adolescent or pediatric | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 09 | Td (adult) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 10 | IPV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 100 | pneumococcal conjugate | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 101 | typhoid, ViCPs | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 102 | DTP-Hib-Hep B | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 103 | meningococcal C conjugate | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 104 | Hep A-Hep B | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 105 | vaccinia (smallpox) diluted | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 106 | DTaP, 5 pertussis antigens6 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 107 | DTaP, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 108 | meningococcal, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 109 | pneumococcal, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 11 | pertussis | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 110 | DTaP-Hep B-IPV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 111 | influenza, live, intranasal | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 112 | tetanus toxoid, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 113 | Td (adult) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 114 | meningococcal A,C,Y,W-135 diphtheria conjugate | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 115 | Tdap | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 116 | rotavirus, pentavalent | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 117 | VZIG (IND) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 118 | HPV, bivalent | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 119 | rotavirus, monovalent | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 12 | diphtheria antitoxin | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 120 | DTaP-Hib-IPV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 121 | zoster | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 122 | rotavirus, NOS1 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 13 | TIG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 14 | IG, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 15 | influenza, split (incl. purified surface antigen) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 16 | influenza, whole | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 17 | Hib, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 18 | rabies, intramuscular injection | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 19 | BCG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 20 | DTaP | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 21 | varicella | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 22 | DTP-Hib | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 23 | plague | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 24 | anthrax | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 25 | typhoid, oral | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 26 | cholera | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 27 | botulinum antitoxin | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 28 | DT (pediatric) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 29 | CMVIG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 30 | HBIG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 31 | Hep A, pediatric, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 32 | meningococcal | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 33 | pneumococcal | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 34 | RIG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 35 | tetanus toxoid | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 36 | VZIG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 37 | yellow fever | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 38 | rubella/mumps | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 39 | Japanese encephalitis | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 40 | rabies, intradermal injection | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 41 | typhoid, parenteral | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 42 | Hep B, adolescent/high risk infant2 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 43 | Hep B, adult4 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 44 | Hep B, dialysis | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 45 | Hep B, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 46 | Hib (PRP-D) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 47 | Hib (HbOC) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 48 | Hib (PRP-T) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 49 | Hib (PRP-OMP) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 50 | DTaP-Hib | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 51 | Hib-Hep B | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 52 | Hep A, adult | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 53 | typhoid, parenteral, AKD (U.S. military) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 54 | adenovirus, type 4 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 55 | adenovirus, type 7 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 56 | dengue fever | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 57 | hantavirus | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 58 | Hep C | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 59 | Hep E | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 60 | herpes simplex 2 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 61 | HIV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 62 | HPV, quadrivalent | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 63 | Junin virus | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 64 | leishmaniasis | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 65 | leprosy | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 66 | Lyme disease | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 67 | malaria | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 68 | melanoma | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 69 | parainfluenza-3 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 70 | Q fever | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 71 | RSV-IGIV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 72 | rheumatic fever | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 73 | Rift Valley fever | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 74 | rotavirus, tetravalent | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 75 | vaccinia (smallpox) | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 76 | Staphylococcus bacterio lysate | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 77 | tick-borne encephalitis | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 78 | tularemia vaccine | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 79 | vaccinia immune globulin | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 80 | VEE, live | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 81 | VEE, inactivated | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 82 | adenovirus, NOS1 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 83 | Hep A, ped/adol, 2 dose | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 84 | Hep A, ped/adol, 3 dose | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 85 | Hep A, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 86 | IG | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 87 | IGIV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 88 | influenza, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 89 | polio, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 90 | rabies, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 91 | typhoid, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 92 | VEE, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 93 | RSV-MAb | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 94 | MMRV | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 95 | TST-OT tine test | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 96 | TST-PPD intradermal | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 97 | TST-PPD tine test | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 98 | TST, NOS | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 99 | RESERVED - do not use3 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 998 | no vaccine administered5 | ||
http://hl7.org/fhir/v2/0292 | 1.0.2 | 999 | unknown |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |